Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress – Eikon Therapeutics Clinical Pipeline Updates at ESMO 26 Congress in Madrid, Spain

Eikon Therapeutics has had seven abstracts accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.

The abstracts cover updates across Eikon’s clinical pipeline, including EIK1001, EIK1003, EIK1004, and EIK1005.

Presentations include updated Phase 2 data from TeLuRide-005 (EIK1001 plus pembrolizumab and chemotherapy in stage IV NSCLC), Phase 1/2 data for PARP1 inhibitors EIK1003 and EIK1004, and initial safety and pharmacokinetic data for the Werner helicase inhibitor EIK1005.